AIM ImmunoTech logo
AIM ImmunoTech AIM
$ 0.87 -10.65%

Quarterly report 2025-Q3
added 11-17-2025

report update icon

AIM ImmunoTech Financial Statements 2011-2026 | AIM

Annual Financial Statements AIM ImmunoTech

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

20.2 M 44.2 M 79 M 3.68 M 9.72 M 14.6 M 14.4 M 21.3 M 41.4 M 73.6 M 42.3 M 63.7 M

Shares

48.1 M 48 M 38.9 M 3.64 M 1 M 652 K 496 K 447 K 357 K 317 K 267 K 256 K

Historical Prices

0.42 0.92 1.79 0.54 7.92 15.4 30.4 42.2 132 143 132 106

Net Income

-19.4 M -19.1 M -14.4 M -9.53 M -9.81 M -8.26 M -7.5 M -15.2 M -17.4 M -16.2 M -17.4 M -9.02 M

Revenue

141 K 135 K 163 K 140 K 367 K 437 K 92 K 133 K 197 K 150 K 213 K 161 K

Cost of Revenue

- - - - - - - - 1.25 M 1.23 M 1.99 M 1.04 M

Gross Profit

- - -643 K -753 K -517 K -746 K -1.02 M -1.46 M -1.05 M -1.08 M -1.78 M -882 K

Operating Income

-19.9 M -18.8 M -15.2 M -12.4 M -11.5 M -11.4 M -13.8 M -16.6 M -19.1 M -17.2 M -20.3 M -14.3 M

Interest Expense

629 K 67 K 672 K 427 K 201 K - - 3 K 11 K 16 K 24 K 41 K

EBITDA

-19.9 M -18.2 M 1.85 M -11.7 M -10.6 M -10.4 M -12.5 M -15.5 M -18 M -16.3 M -19.7 M -13.7 M

Operating Expenses

- - 14.4 M 11.7 M 11 M 10.7 M 12.8 M 15.2 M 18 M 16.1 M 18.6 M 13.4 M

General and Administrative Expenses

13.1 M 8.67 M 8.65 M 7.04 M 6.2 M 6.57 M - - - - - -

All numbers in USD currency

Quarterly Income Statement AIM ImmunoTech

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

2.09 M 759 K 70.3 M 655 K 577 K 528 K 49.5 M 49.1 M 48.6 M 48.4 M 48.4 M 48.1 M 48.1 M 48 M 48 M 48 M 47.8 B 47.8 M 45.7 M 42.2 M 38.9 B 30 M 17.5 M 10.4 M 2.6 M 1.9 M 1.16 M 1.11 M 1.07 M 1.02 M 36.3 M 32.9 M 30.1 M 27.3 M 25.3 M 24.2 M 21.8 M 20.7 M 20.6 M 20.6 M 20.6 M 236 M 214 M 204 M 191 M 186 M 177 M 169 M 167 M 167 M 167 M 166 M 137 M 136 M 136 M 136 M 135 M 135 M 135 M

Net Income

-3.28 M -2.79 M -3.7 M - -3.7 M -1.84 M -5.82 M - -7.82 M -4.91 M -3.66 M - -6.38 M -4.85 M -3.82 M - -3.83 M -5.88 M -3.58 M - -3.31 M -3.37 M -3.81 M - -2.95 M -2.04 M -3.36 M - -3.08 M -2.42 M -2.71 M - -1.25 M -2.19 M -2.82 M - -2.86 M -1.3 M -2.16 M - -3.8 M -4.84 M -3.44 M - -4.2 M -4.96 M -3.84 M -3.2 M -5.14 M -4.28 M -3.61 M -5.46 M -6.59 M -3 M -2.31 M -3.12 M -2.74 M -2.29 M -866 K

Revenue

26 K 25 K 16 K - 35 K 50 K 40 K - 46 K 42 K 49 K - 21 K 30 K 33 K - 33 K 23 K 28 K - 36 K 40 K 45 K - 61 K 29 K - - 38 K 33 K 56 K - 90 K 213 K 84 K - 22 K 15 K 39 K - 23 K 47 K 36 K - 45 K 36 K 76 K 36 K 36 K 36 K 42 K 53 K 39 K 49 K 72 K 38 K 45 K 36 K 42 K

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 353 K 507 K 372 K - 306 K 294 K 323 K - 252 K 635 K 191 K - 988 K 208 K 280 K - 217 K 204 K 193 K

Operating Income

-2.45 M -2.65 M -3.62 M - -4.49 M -3.69 M -5.73 M - -8.16 M -5.46 M -4.3 M - -6.52 M -4.7 M -3.15 M - -3.93 M -3.72 M -3.74 M - -3.36 M -3.34 M -3.32 M - -3.2 M -3.22 M -2.93 M - -3.04 M -3.23 M -2.57 M - -2.65 M -2.73 M -3.24 M - -3.23 M -2.81 M -3.68 M - -3.98 M -4.9 M -4.92 M - -4.33 M -5.08 M -5.11 M - -4.46 M -4.73 M -4.56 M - -4.96 M -3.63 M -3.75 M - -3.56 M -3.25 M -3.59 M

Interest Expense

148 K 149 K 124 K - 202 K 179 K 72 K - 294 K 318 K 199 K - 172 K 79 K - - 67 K 19 K 50 K - 51 K 249 K 322 K - - - 4.28 K - 4.3 M - - - - - - - - - - - 1 K 2 K 2 K - - - - 165 K 85 K 349 K 49 K 719 K -68 K -33 K 11 K -82 K 21 K 12 K 6 K

EBITDA

- - -3.61 M - - - -5.72 M - - - -4.28 M - -6.49 M -4.68 M -3.14 M - -3.44 M -3.39 M -3.58 M - -2.86 M -3 M -3.15 M - -2.65 M -2.84 M -2.73 M - -2.38 M -2.78 M -2.35 M - -1.91 M -2.23 M -2.98 M - -2.37 M -2.24 M -3.38 M - -3.32 M -4.44 M -4.74 M - -3.83 M -4.75 M -4.94 M - -3.96 M -4.38 M -4.38 M - -4.5 M -3.34 M -3.6 M - -3.24 M -3.05 M -3.48 M

General and Administrative Expenses

1.8 M 1.49 M 2.54 M - 3.08 M 2.59 M 3.82 M - 5.44 M 2.55 M 2.29 M - 5.17 M 2.18 M 2.07 M - 1.8 M 2.14 M 2.11 M - 2.08 M 1.72 M 2.27 M - 1.85 M 1.94 M 1.77 M - 1.27 M 1.73 M 1.56 M - 1.56 M 1.62 M 1.66 M - 1.63 M 1.64 M 2.45 M - 1.68 M 2 M 1.91 M - 2.17 M 2.5 M 2.54 M - 2.07 M 1.82 M 2.08 M - 1.66 M 1.74 M 1.87 M - 1.64 M 1.46 M 1.8 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements AIM ImmunoTech AIM
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting AIM ImmunoTech plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.14 2.6 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 2.37 1.72 % $ 3.1 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.6 1.92 % $ 916 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 10.35 2.88 % $ 755 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
$ 1.27 4.09 % $ 7.6 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.35 1.89 % $ 344 M britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.23 0.61 % $ 110 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 47.4 2.09 % $ 4.26 B schweizSchweiz
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
- -5.98 % $ 34.1 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 1.32 3.13 % $ 81 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
$ 1.39 -0.36 % $ 73 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Enochian Biosciences Enochian Biosciences
ENOB
- - $ 40.5 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.26 4.49 % $ 251 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.53 2.35 % $ 99.5 M niderlandNiderland
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.51 4.76 % $ 864 M canadaCanada
Homology Medicines Homology Medicines
FIXX
- 0.77 % $ 53.4 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA